Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
RIGL's Cash to Debt is ranked higher than
99% of the 790 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.44 vs. RIGL: No Debt )
Ranked among companies with meaningful Cash to Debt only.
RIGL' s Cash to Debt Range Over the Past 10 Years
Min: 4.48  Med: 68.58 Max: No Debt
Current: No Debt
Equity to Asset 0.74
RIGL's Equity to Asset is ranked higher than
68% of the 724 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. RIGL: 0.74 )
Ranked among companies with meaningful Equity to Asset only.
RIGL' s Equity to Asset Range Over the Past 10 Years
Min: 0.43  Med: 0.75 Max: 0.94
Current: 0.74
0.43
0.94
Interest Coverage No Debt
RIGL's Interest Coverage is ranked higher than
99% of the 650 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 94.32 vs. RIGL: No Debt )
Ranked among companies with meaningful Interest Coverage only.
RIGL' s Interest Coverage Range Over the Past 10 Years
Min: 388.1  Med: No Debt Max: No Debt
Current: No Debt
F-Score: 3
Z-Score: -10.09
M-Score: -2.87
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -257.33
RIGL's Operating margin (%) is ranked lower than
91% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.64 vs. RIGL: -257.33 )
Ranked among companies with meaningful Operating margin (%) only.
RIGL' s Operating margin (%) Range Over the Past 10 Years
Min: -14938.27  Med: -1106.05 Max: 28.25
Current: -257.33
-14938.27
28.25
Net-margin (%) -255.84
RIGL's Net-margin (%) is ranked lower than
91% of the 737 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.21 vs. RIGL: -255.84 )
Ranked among companies with meaningful Net-margin (%) only.
RIGL' s Net-margin (%) Range Over the Past 10 Years
Min: -14872.93  Med: -1101.92 Max: 30.31
Current: -255.84
-14872.93
30.31
ROE (%) -82.29
RIGL's ROE (%) is ranked lower than
92% of the 763 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.92 vs. RIGL: -82.29 )
Ranked among companies with meaningful ROE (%) only.
RIGL' s ROE (%) Range Over the Past 10 Years
Min: -142.04  Med: -44.8 Max: 27.46
Current: -82.29
-142.04
27.46
ROA (%) -58.46
RIGL's ROA (%) is ranked lower than
91% of the 798 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.58 vs. RIGL: -58.46 )
Ranked among companies with meaningful ROA (%) only.
RIGL' s ROA (%) Range Over the Past 10 Years
Min: -101.94  Med: -37.37 Max: 23.14
Current: -58.46
-101.94
23.14
ROC (Joel Greenblatt) (%) -4213.58
RIGL's ROC (Joel Greenblatt) (%) is ranked lower than
95% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.01 vs. RIGL: -4213.58 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
RIGL' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -4317.77  Med: -2183.36 Max: 1113
Current: -4213.58
-4317.77
1113
Revenue Growth (3Y)(%) 121.70
RIGL's Revenue Growth (3Y)(%) is ranked higher than
99% of the 606 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.50 vs. RIGL: 121.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
RIGL' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -45 Max: 121.7
Current: 121.7
0
121.7
EBITDA Growth (3Y)(%) -23.90
RIGL's EBITDA Growth (3Y)(%) is ranked lower than
89% of the 575 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.50 vs. RIGL: -23.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
RIGL' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -47  Med: -22.8 Max: 23.2
Current: -23.9
-47
23.2
EPS Growth (3Y)(%) -24.00
RIGL's EPS Growth (3Y)(%) is ranked lower than
84% of the 539 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.30 vs. RIGL: -24.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
RIGL' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -56.5  Med: -22.75 Max: 21.8
Current: -24
-56.5
21.8
GuruFocus has detected 3 Warning Signs with Rigel Pharmaceuticals Inc $RIGL.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» RIGL's 10-Y Financials

Financials (Next Earnings Date: 2017-03-08)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

RIGL Guru Trades in Q1 2016

John Paulson 999,700 sh (+89.09%)
Paul Tudor Jones 29,251 sh (+38.54%)
Jim Simons 660,800 sh (+32.27%)
Charles Brandes Sold Out
» More
Q2 2016

RIGL Guru Trades in Q2 2016

Jim Simons 792,600 sh (+19.95%)
John Paulson 999,700 sh (unchged)
Paul Tudor Jones 29,251 sh (unchged)
» More
Q3 2016

RIGL Guru Trades in Q3 2016

Paul Tudor Jones 42,241 sh (+44.41%)
John Paulson 805,000 sh (-19.48%)
Jim Simons 629,800 sh (-20.54%)
» More
Q4 2016

RIGL Guru Trades in Q4 2016

Paul Tudor Jones Sold Out
Jim Simons Sold Out
John Paulson 387,697 sh (-51.84%)
» More
» Details

Insider Trades

Latest Guru Trades with RIGL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NAS:ARLZ, NAS:ZYNE, NAS:INNL, OTCPK:MQTRF, NAS:SNDX, NAS:ADMS, NAS:TTPH, OTCPK:OGRMF, NAS:COLL, NAS:AQXP, NAS:KPTI, NAS:SMMT, NAS:DRRX, NAS:LBIO, OTCPK:SENZ, OTCPK:ORXOY, OTCPK:ELTP, OTCPK:OWCP, NAS:ACET, NAS:MSLI » details
Traded in other countries:RI2A.Germany,
Rigel Pharmaceuticals Inc is a clinical-stage drug development company. It discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases, as well as for certain cancers and metabolic diseases.

Rigel Pharmaceuticals Inc was incorporated in the state of Delaware on June 14, 1996. The Company is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. The Companys pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. The Company currently has five product candidates in development: fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor entering in Phase 3 clinical trials for immune thrombocytopenic purpura (ITP) and a Phase 2 clinical trial for immunoglobulin A nephropathy (IgAN) in the first half of 2014; R348, a topical JAK/SYK inhibitor currently in Phase 2 clinical trials for dry eye; R118, an adenosine monophosphate (AMP)-activated protein kinase (AMPK) activator entering Phase 1 in the first half of 2014; and two oncology product candidates in Phase 1 development with partners BerGenBio AS and Daiichi Sankyo, respectively. The Company is conducting proprietary research in the broad disease areas of inflammation/immunology and muscle wasting/muscle endurance. The Companys competitors include fully integrated pharmaceutical companies that have extensive drug discovery efforts and are developing novel small molecule pharmaceuticals. The Company is subject to extensive regulation by numerous governmental authorities in the United States and other countries, including the FDA under the Federal Food, Drug and Cosmetic Act.

Ratios

vs
industry
vs
history
P/B 3.54
RIGL's P/B is ranked lower than
59% of the 827 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.02 vs. RIGL: 3.54 )
Ranked among companies with meaningful P/B only.
RIGL' s P/B Range Over the Past 10 Years
Min: 1.02  Med: 2.6 Max: 10.47
Current: 3.54
1.02
10.47
P/S 8.26
RIGL's P/S is ranked lower than
77% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.06 vs. RIGL: 8.26 )
Ranked among companies with meaningful P/S only.
RIGL' s P/S Range Over the Past 10 Years
Min: 2.8  Med: 28.19 Max: 543.89
Current: 8.26
2.8
543.89
Current Ratio 4.19
RIGL's Current Ratio is ranked higher than
72% of the 726 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.49 vs. RIGL: 4.19 )
Ranked among companies with meaningful Current Ratio only.
RIGL' s Current Ratio Range Over the Past 10 Years
Min: 1.84  Med: 7.48 Max: 36.3
Current: 4.19
1.84
36.3
Quick Ratio 4.19
RIGL's Quick Ratio is ranked higher than
76% of the 725 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.84 vs. RIGL: 4.19 )
Ranked among companies with meaningful Quick Ratio only.
RIGL' s Quick Ratio Range Over the Past 10 Years
Min: 1.84  Med: 7.48 Max: 36.3
Current: 4.19
1.84
36.3
Days Sales Outstanding 1.34
RIGL's Days Sales Outstanding is ranked higher than
98% of the 628 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.32 vs. RIGL: 1.34 )
Ranked among companies with meaningful Days Sales Outstanding only.
RIGL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 1.34  Med: 12.8 Max: 293.53
Current: 1.34
1.34
293.53

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.30
RIGL's 3-Year Average Share Buyback Ratio is ranked higher than
68% of the 436 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.40 vs. RIGL: -1.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
RIGL' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -153.2  Med: -19.05 Max: -1.3
Current: -1.3
-153.2
-1.3

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.73
RIGL's Price/Net Cash is ranked higher than
81% of the 250 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.84 vs. RIGL: 3.73 )
Ranked among companies with meaningful Price/Net Cash only.
RIGL' s Price/Net Cash Range Over the Past 10 Years
Min: 1.2  Med: 3.36 Max: 15.44
Current: 3.73
1.2
15.44
Price/Net Current Asset Value 3.62
RIGL's Price/Net Current Asset Value is ranked higher than
77% of the 542 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. RIGL: 3.62 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
RIGL' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.2  Med: 3.22 Max: 13.37
Current: 3.62
1.2
13.37
Price/Tangible Book 3.51
RIGL's Price/Tangible Book is ranked higher than
51% of the 747 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.65 vs. RIGL: 3.51 )
Ranked among companies with meaningful Price/Tangible Book only.
RIGL' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.16  Med: 2.91 Max: 11.62
Current: 3.51
1.16
11.62
Price/Median PS Value 0.29
RIGL's Price/Median PS Value is ranked higher than
96% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.13 vs. RIGL: 0.29 )
Ranked among companies with meaningful Price/Median PS Value only.
RIGL' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.04  Med: 0.61 Max: 18.65
Current: 0.29
0.04
18.65
Earnings Yield (Greenblatt) (%) -33.18
RIGL's Earnings Yield (Greenblatt) (%) is ranked lower than
92% of the 835 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. RIGL: -33.18 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
RIGL' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -33.8  Med: 15.5 Max: 6128.3
Current: -33.18
-33.8
6128.3

More Statistics

Revenue (TTM) (Mil) $25.92
EPS (TTM) $ -0.72
Beta1.27
Short Percentage of Float4.38%
52-Week Range $1.88 - 4.38
Shares Outstanding (Mil)121.94

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 21 29 64 66
EPS ($) -0.66 -0.34 -0.12 -0.14
EPS w/o NRI ($) -0.66 -0.34 -0.12 -0.14
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for RIGL

Headlines

Articles On GuruFocus.com
Biocept (BIOC) Soars on Liquid Biopsy Appreciation, Rigel Pharmaceuticals (RIGL) Mega-deal with Bris Feb 23 2015 
Rigel Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 01 2011 

More From Other Websites
RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Feb 08 2017
Rigel Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Option To Purchase... Feb 03 2017
RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 31 2017
Rigel Announces Pricing Of Public Offering Of Common Stock Jan 31 2017
RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Other... Jan 30 2017
Rigel Announces Proposed Public Offering Of Common Stock Jan 30 2017
Why the Rigel Pharmaceuticals Update Could Signal Further Growth Jan 30 2017
Fostamatinib Study Results Continue to Trend Positive Jan 30 2017
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Jan 16 2017
Rigel Provides Business Updates and Preliminary Data in IgA Nephropathy Jan 05 2017
Rigel Provides Business Updates and Preliminary Data in IgA Nephropathy Jan 05 2017
Is Rigel Pharmaceuticals, Inc. (RIGL) Worthy of Your Portfolio? Dec 14 2016
Hedge Funds Think The Sky’s The Limit For Horizon Global Corp (HZN) Nov 28 2016
Rigel to Present at Jefferies 2016 London Healthcare Conference Nov 10 2016
RIGEL PHARMACEUTICALS INC Financials Nov 08 2016
ETF’s with exposure to Rigel Pharmaceuticals, Inc. : November 4, 2016 Nov 04 2016
Rigel Pharmaceuticals, Inc. :RIGL-US: Earnings Analysis: Q3, 2016 By the Numbers : November 3, 2016 Nov 03 2016
Edited Transcript of RIGL earnings conference call or presentation 1-Nov-16 9:00pm GMT Nov 02 2016
RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 01 2016
Rigel Announces Third Quarter 2016 Financial Results and Provides Company Update Nov 01 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)